PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Expert Rev Gastroenterol Hepatol. Author manuscript; available in PMC 2016 July 17.
Published in final edited form as:
PMCID: PMC4832565
NIHMSID: NIHMS774989

Protein kinase D enzymes – novel kinase targets in pancreatic cancer

Summary

Pancreatic ductal adenocarcinoma (PDA) is characterized by advanced stage desmoplastic tumors with a high prevalence of genetic abnormalities. Occurrence of PDA is linked to activating Kras mutations and aberrant epidermal growth factor receptor signaling, leading to additional activation of wildtype Kras. Since Kras is difficult to target, there is a constant need to identify novel targets acting downstream of this molecule in driving the formation or progression of PDA. Recently, it was shown that Protein kinase D enzymes not only are increasingly expressed in PDA, but also causatively linked to the development and progression of this cancer. They act downstream of both mutant Kras and growth factors and therefore may represent ideal novel targets.

Keywords: Protein Kinase D, PKD, isoforms, pancreatic cancer, acinar-to-ductal metaplasia

Introduction

Pancreatic cancer has one of the highest mortality rates among all major types of cancers. The overall 5 year survival rate of pancreatic cancer patients is at approximately 5% and has not been significantly improved over decades. Approximately 95% of pancreatic cancers diagnosed are pancreatic ductal adenocarcinoma (PDA) with activating Kras mutations. Current opinion is that PDA originates from pancreatic acini which harbor oncogenic Kras mutations. These cells undergo acinar-to-ductal metaplasia (ADM), which transdifferentiates them into duct-like cells with progenitor properties that form early pancreatic intraepithelial neoplasia (PanIN) lesions. PanIN cells also acquire an upregulation of EGFR2 (HER2/neu) signaling. Eventually, after sequential acquisition of additional mutations such as inactivation of the tumor suppressor genes p53 and/or SMAD4 (late stage mutations typically occurring in advanced PanIN3) PanINs further progress to pancreatic cancer (reviewed in [1]). Eventually, it was shown that in order to develop carcinoma in situ and PDA, pancreatic cells also need to be exposed to inflammation, which inhibits oncogene-induced senescence [2].

Protein Kinase D (PKD) enzymes are serine/threonine protein kinases that belong to the calmodulin-dependent protein kinases (CAMK) superfamily and modulate various biological processes. Mammalian PKD isoforms include PKD1, PKD2 and PKD3, which all share similar domain homology and arrangements, but also have certain distinct physiological functions. Among these isoforms, PKD1 and PKD2 have been best characterized in respect to their roles in the development and progression of PDA. For example, PKD1 has been shown to be activated downstream of both oncogenic Kras and growth factor signaling in the initiation of pancreatic cancer [3]. In addition, cholecystokinin (CCK), a signaling molecule that mediates the release of pancreatic digestive enzymes can activate PKD1 in pancreatic acini, leading to activation of NF-κB [4], a signaling pathway that may contribute to ADM and possibly upregulation of inflammatory cytokines. In PDA cell lines it was shown that PKD1 regulates many aspects of progression, including cell proliferation, survival and invasion [5,6]. In addition, a recent study demonstrated that PKD2 increases invasiveness of pancreatic cancer cells [7].

Roles of PKD isoforms in the normal pancreas

Relatively little is known on the functions of PKD enzymes in the normal pancreas. In mouse pancreas, under physiological conditions, all three PKD isoforms are present. However, expression of each isoform is associated with different types of pancreatic cells, indicating specific roles for different PKDs in executing distinct biological functions in the pancreas. PKD1 is mainly expressed in ducts [3] and islets of Langerhans. Activation of PKD1 in isolated pancreatic islets from p38δ knockout mice elevates insulin secretion and promotes pancreatic β cell survival [8]. PKD2 is expressed in acinar cells and in islets, but its functions are not characterized [3]. PKD3 is mainly expressed in acini in which it regulates amylase secretion in response to gastrointestinal hormone stimulation [3,9]. It should be noted that expression patterns of PKD isoforms in the different cell types of normal pancreas is species-specific and may be different between rodents and humans [4,10].

Roles of PKD enzymes in development and progression of PDA

Although not present in normal mouse acinar cells, PKD1 expression is upregulated in acinar cells undergoing transformation to a duct-like phenotype [3]. Such acinar-to-ductal metaplasia is a first step in PDA initiation and can be induced by growth factors (i.e. TGFα), cytokines (i.e. TNFα), chemokines (i.e. RANTES) and oncogenic Kras mutations [3,1113]. In TGFα-induced ADM, both in 3D organoid culture of primary pancreatic acini and in pancreatic tissue from TGFα transgenic mice, only PKD1 (but not the other two isoforms PKD2 and PKD3) is detected with increased levels of protein expression and activity [3]. Similarly, elevated levels of total and active PKD1 are present in KrasG12D-driven models for ADM and initiation of PDA. Either knockdown of PKD1 via lentivirally-delivered small interference RNA or inhibition of PKD1 kinase activity diminishes KrasG12D-driven ADM in an ex vivo 3D organoid culture system [3]. Moreover, in vivo an acinar cell-specific knockout of PKD1 reduces not only KrasG12D-caused ADM, but also progression of pancreatic intraepithelial neoplasias, revealing a role of PKD1 in potentiating the establishment of high grade PanIN lesions [3]. It should be noted, that so far it is unclear if PKD1 or one of the two other isoforms drives ADM in human PDA. In pancreatic cancer cell lines the overexpression of PKD1 promotes all properties of transformation including anchorage-independent growth, invasiveness and proliferation [5,6]. Some of these effects can be mediated by neurotensin, a neuropeptide overexpressed in pancreatic cancer, which promotes cell growth of human pancreatic cancer cells by activation of a PKC-PKD1 signaling pathway [14,15]. In addition, ectopic expression of PKD1 in Panc-1 cells upregulates VEGF and IL-8 to modulate angiogenesis, which contributes to PDA progression [5]. Relatively little is known on the roles of other PKD isoforms in the development or progression of PDA, but recently it was shown that overexpression of PKD2 also increases the invasiveness of Panc89 cells through upregulation of MMP7 and MMP9 [7].

PKD inhibitors - promising new tools for treatment of PDA?

The role of PKD1 downstream of Kras and EGFR signaling provides rationale for a development of PKD inhibitors for clinical use. Several new small molecules targeting pan PKD including CRT0066101, CRT5, CID755673, and kb-NB142-70 have been recently developed [1619]. Some of these compounds have been shown to inhibit key-events of PDA development and progression in in vitro cell culture, ex vivo 3D organoid culture and in vivo. For example, treatment of cultured human pancreatic cancer cells with the pan PKD inhibitor CRT0066101 induces apoptosis and reduces transformed abilities including proliferation, anchorage independent growth and invasiveness [5,18]. Inhibition of PKD1 with the pan PKD inhibitors kb-NB142-70 and CRT0066101 diminished both KrasG12D- and TGFα-induced ADM in 3D organoid culture of primary acini, indicating that inhibition of PKD1 prevents development of PDA [3]. Moreover, in mice with human Panc-1 xenografts an oral administration of CRT0066101 abolished formation of micro blood vessel and pancreatic cancer growth [5,18].

Many compounds previously described as PKD inhibitors often show PKD-inhibiting activities in vitro and in cells, but, due to rapid drug metabolism in living organisms, they fail when administered in animal models [1619,22]. So far, only CRT0066101 and CID755673 have been successfully used in animals including human pancreatic cancer xenografts [5,10,18]. Of these, CID755673 has been described to show off-target effects. So far, no off-target effects have been observed for CRT0066101. In addition, mice treated with CRT0066101 did not show any signs of distress, and no side effects on normal tissue structure of function (i.e. effects on ductal functions) were noted in vivo in xenograft models for pancreatic, colorectal and metastatic breast cancers [18,20,21].

None of the present PKD inhibitors so far have been successfully-developed for clinical use. Therefore, key tasks within the next five years are to further develop the use of CRT0066101, to identify novel PKD-specific inhibitors, to provide preclinical data using animal models that also consider the host’s microenvironment, and to develop them for clinical trials, either alone or in combination with current standard of care.

Summary

Although existing preclinical data provide a rationale for developing pan PKD inhibitors for clinical use to treat pancreatic cancer patients, some questions related to PKD functions in development and progression of PDA remain unanswered. For example, the initiation of PDA through acinar-to-ductal metaplasia is driven by PKD1, which acts downstream of mutant Kras and EGFR signaling pathways [3]. While it clearly was demonstrated that the other two isoforms, PKD2 and PKD3, are not involved in this initiation process, it remains to be determined whether these two isoforms are associated with progression to carcinoma in situ, PDA or metastasis. Therefore, it would be of great importance to assess the PKD isoforms and their functions in transgenic mice of metastatic pancreatic cancer such as KrasG12D;p53R172H;Pdx1cre (KPC) and KrasG12D;INK4/Arf−/−;Pdx1cre models which mimic metastatic disease, similar as presented in the clinic. These animal models also hold great potential for testing PKD-targeting drugs since they resemble all aspects of human pancreatic cancer including extensive stromal desmoplasia. In addition patient-derived xenograft (PDX) models could be used for testing response to treatment. However, it should be noted that PDX models typically do not show metastases, and may only be suitable for determining response of primary tumors to treatment. A key question for the use of PKD inhibitors that needs to be answered with above animal models is if inhibition of PKD leads to a halt of tumor growth and metastases, or if it also induced regression of established tumors and metastases.

In summary, so far accumulated preclinical data acquired with pancreatic cancer cells lines, genetic and orthotopic animal models, as well as patient samples suggest PKD enzymes as targets in PDA. Therefore, PKD inhibitors hold great potential as therapeutic drugs for pancreatic cancer patients. Moreover, since they may prevent ADM and inflammatory signaling, PKD inhibitors may also be beneficial as a preventive measure to the high risk populations for pancreatic cancer such as hereditary pancreatitis patients, but also for patients with acute pancreatitis.

Acknowledgments

The authors were supported by the National Institutes of Health (grant number: R01 CA140182).

Footnotes

Financial and competing interests disclosure

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Quotes

“New therapeutic targets are needed for pancreatic cancer”

“Protein Kinase D1 regulates the initiation of pancreatic ductal adenocarcinoma”

“PKD enzymes promote tumor growth, survival and invasion of PDA”

“Targeting PKD may affect tumor development and progression”

References

Papers of special note have been highlighted as:

*of interest

**of considerable interest

1. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006;20(10):1218–1249. [PubMed]
2. Guerra C, Collado M, Navas C, et al. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell. 2011;19(6):728–739. [PMC free article] [PubMed]
3. Liou GY, Doppler H, Braun UB, et al. Protein kinase D1 drives pancreatic acinar cell reprogramming and progression to intraepithelial neoplasia. Nat Commun. 2015;6:6200. [PubMed] ** Demonstrates the importance of PKD1 in converging mutant Kras and growth factor signaling in the initiation of PDA. Also shows that a knockout of PKD1 in pancreatic acinar cells impedes the formation of high grade PanINs.
4. Berna MJ, Hoffmann KM, Tapia JA, et al. CCK causes PKD1 activation in pancreatic acini by signaling through PKC-delta and PKC-independent pathways. Biochim Biophys Acta. 2007;1773(4):483–501. [PMC free article] [PubMed]
5. Ochi N, Tanasanvimon S, Matsuo Y, et al. Protein kinase D1 promotes anchorage-independent growth, invasion, and angiogenesis by human pancreatic cancer cells. J Cell Physiol. 2011;226(4):1074–1081. [PubMed]
6. Trauzold A, Schmiedel S, Sipos B, et al. PKCmu prevents CD95-mediated apoptosis and enhances proliferation in pancreatic tumour cells. Oncogene. 2003;22(55):8939–8947. [PubMed] * Demonstrates the importance of PKD1 in regulating proliferation and survival of PDA cells.
7. Wille C, Kohler C, Armacki M, et al. Protein kinase D2 induces invasion of pancreatic cancer cells by regulating matrix metalloproteinases. Mol Biol Cell. 2014;25(3):324–336. [PubMed] * Implicates that a switch from PKD1 to PKD2 may be a driving force for increasing cancer cell invasiveness.
8. Sumara G, Formentini I, Collins S, et al. Regulation of PKD by the MAPK p38delta in insulin secretion and glucose homeostasis. Cell. 2009;136(2):235–248. [PMC free article] [PubMed]
9. Chen LA, Li J, Silva SR, et al. PKD3 is the predominant protein kinase D isoform in mouse exocrine pancreas and promotes hormone-induced amylase secretion. J Biol Chem. 2009;284(4):2459–2471. [PubMed] * Characterizes PKD isoforms in normal pancreas.
10. Yuan J, Liu Y, Tan T, et al. Protein kinase d regulates cell death pathways in experimental pancreatitis. Front Physiol. 2012;3:60. [PubMed] * Characterizes the role of PKD1 in pancreatitis.
11. Ardito CM, Gruner BM, Takeuchi KK, et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell. 2012;22(3):304–317. [PubMed] ** Demonstrates the crosstalk between mutant and wildtype Kras in the development of PDA.
12. Liou GY, Doppler H, Necela B, et al. Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions. Cancer Discov. 2015;5(1):52–63. [PMC free article] [PubMed]
13. Liou GY, Doppler H, Necela B, et al. Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-kappaB and MMPs. J Cell Biol. 2013;202(3):563–577. [PubMed] * Demonstrates the induction of acinar cell metaplasia with TNFα and RANTES.
14. Guha S, Rey O, Rozengurt E. Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1. Cancer Res. 2002;62(6):1632–1640. [PubMed]
15. Ishizuka J, Townsend CM, Jr, Thompson JC. Neurotensin regulates growth of human pancreatic cancer. Ann Surg. 1993;217(5):439–445. discussion 446. [PubMed]
16. Evans IM, Bagherzadeh A, Charles M, et al. Characterization of the biological effects of a novel protein kinase D inhibitor in endothelial cells. Biochem J. 2010;429(3):565–572. [PMC free article] [PubMed]
17. George KM, Frantz MC, Bravo-Altamirano K, et al. Design, Synthesis, and Biological Evaluation of PKD Inhibitors. Pharmaceutics. 2011;3(2):186–228. [PMC free article] [PubMed]
18. Harikumar KB, Kunnumakkara AB, Ochi N, et al. A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther. 2010;9(5):1136–1146. [PubMed] ** Describes the use of the PKD inhibitor CRT0066101 in an orthotopic animal model for PDA.
19. Sharlow ER, Giridhar KV, LaValle CR, et al. Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone. J Biol Chem. 2008;283(48):33516–33526. [PMC free article] [PubMed]
20. Borges S, Perez EA, Thompson EA, Radisky DC, Geiger XJ, Storz P. Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101. Mol Cancer Ther. 2015;14(6):1306–1316. [PMC free article] [PubMed]
21. Wei N, Chu E, Wipf P, Schmitz JC. Protein kinase d as a potential chemotherapeutic target for colorectal cancer. Mol Cancer Ther. 2014;13(5):1130–1141. [PMC free article] [PubMed]
22. Guo J, Clausen DM, Beumer JH, et al. In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts. Cancer Chemother Pharmacol. 2013;71(2):331–344. [PMC free article] [PubMed]